Omnicell (OMCL)
(Delayed Data from NSDQ)
$44.48 USD
-0.78 (-1.72%)
Updated Aug 30, 2024 03:59 PM ET
After-Market: $44.31 -0.17 (-0.38%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$44.48 USD
-0.78 (-1.72%)
Updated Aug 30, 2024 03:59 PM ET
After-Market: $44.31 -0.17 (-0.38%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth A Momentum A VGM
Zacks News
5 Toxic Stocks That Can Set Off Alarm Bells for Your Portfolio
by Rimmi Singhi
Investors who can correctly spot overpriced stocks and shun them at the right time can avoid big losses. Dump toxic stocks like MGM, ILMN, OMCL, HL and RDNT to prevent portfolio bleeding.
Omnicell (OMCL) Ailed by Mounting Costs, Macroeconomic Issues
by Zacks Equity Research
Macroeconomic factors adversely affect bookings and revenues in Omnicell's (OMCL) point-of-care business. The company reduces its overall bookings and revenue outlook for the year.
Omnicell (OMCL) Q3 Earnings Beat Estimates, Guidance Cut
by Zacks Equity Research
Rise in operating expenses result in an operating loss in Q3 for Omnicell (OMCL), placing significant pressure on the bottom line.
Omnicell (OMCL) Q3 Earnings Top Estimates
by Zacks Equity Research
Omnicell (OMCL) delivered earnings and revenue surprises of 6.38% and 4.04%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
MDRX vs. OMCL: Which Stock Is the Better Value Option?
by Zacks Equity Research
MDRX vs. OMCL: Which Stock Is the Better Value Option?
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Should iShares S&P SmallCap 600 Growth ETF (IJT) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IJT
Should SPDR S&P 600 Small Cap Growth ETF (SLYG) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SLYG
Omnicell (OMCL) Q2 Earnings Miss Estimates, Gross Margin Down
by Zacks Equity Research
Robust sales contribution from product and services segments drove Omnicell's (OMCL) Q2 top line.
MDRX vs. OMCL: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
MDRX vs. OMCL: Which Stock Is the Better Value Option?
Omnicell (OMCL) Misses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Omnicell (OMCL) delivered earnings and revenue surprises of -1.18% and 2.37%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Should SPDR S&P 600 Small Cap ETF (SLY) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SLY
Hims & Hers Health, Inc. (HIMS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
Hims & Hers Health, Inc. (HIMS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Omnicell (OMCL) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Omnicell (OMCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Reasons to Add Patterson Companies (PDCO) to Your Portfolio
by Zacks Equity Research
Investors remain optimistic about Patterson Companies (PDCO) on the back of its strong product line.
Should iShares S&P SmallCap 600 Growth ETF (IJT) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IJT
Quest Diagnostics' (DGX) Base Business Grows Despite Margin Woes
by Zacks Equity Research
Quest Diagnostics (DGX) continues to make inroads with its health plans, gaining share and increasing revenues faster than the market.
BD's (BDX) New Combination Test to Boost Patient Outcome
by Zacks Equity Research
BD's (BDX) latest combination test is expected to speed up the detection of the infection-causing viruses, thereby accelerating the implementation of the appropriate treatment plan.
Catalent (CTLT) Expands Packaging Capabilities at Japan Facility
by Zacks Equity Research
Catalent's (CTLT) latest capability expansion is expected to boost its business in this key hub in its Asia-Pacific Clinical Supply Services network.
Exact Sciences (EXAS) Cologuard Growth Robust Amid Margin Woes
by Zacks Equity Research
Exact Sciences' (EXAS) legacy Screening business is growing on impressive Cologuard volume growth and revenue contributions from the PreventionGenetics acquisition.
Cardinal Health (CAH) Ties Up to Deliver Products Via Drones
by Zacks Equity Research
Cardinal Health's (CAH) latest collaboration is expected to significantly boost its distribution strategy and improve patient service.
3 Reasons to Retain Catalent (CTLT) Stock in Your Portfolio
by Zacks Equity Research
Catalent's (CTLT) robust facility expansion activities and a slew of strategic deals raise optimism about the stock.
Omnicell (OMCL) Up 10% Since Q1 Earnings: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Omnicell's (OMCL) strategic partnerships and continued innovations for the Autonomous Pharmacy.
Illumina's (ILMN) GRAIL to Offer Galleri Test in Indianapolis
by Zacks Equity Research
Illumina's (ILMN) division GRAIL will offer the Galleri MCED blood test to eligible patients across the Community Health Network's care sites.